
Mesoblast Investor Relations Material
Latest events

H1 2025
Mesoblast
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Mesoblast Limited
Access all reports
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company's lead product candidate is remestemcel-L, an allogeneic mesenchymal precursor cell therapy that has completed Phase III clinical trial for use in steroid-refractory acute graft versus host disease. It also developed MSC-100-IV that is in Phase II clinical trial to investigate its effects on preventing organ dysfunction and death; MPC-150-IM to treat chronic heart failure; and MPC-06-ID to treat chronic low back pain due to advanced degenerative disc disease. In addition, it has licensed RemestemcelTM to JCR Pharmaceuticals Co., Ltd.; RemestemcelTM-L to JCR Pharmaceuticals Co., Ltd.; revascorTM through a partnership agreement with Pfizer Inc.; and MPC-300-IV through Cytori Therapeutics Inc. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Key slides for Mesoblast Limited


Q4 2024
Mesoblast Limited


International Society for Cell & Gene Therapy North America Virtual Town Hall
Mesoblast Limited
Latest articles
)
James Quincey: Coca-Cola Chairman and CEO
James Quincey has dedicated nearly three decades to The Coca-Cola Company, rising through the ranks to become CEO and Chairman of the company.
11 Mar 2025
)
PepsiCo: From Pepsi and Gatorade to Doritos and Lay's
PepsiCo has grown from a soda company into a global leader in food and beverages, with a portfolio of over 200 brands, including Pepsi, Lay's, and Gatorade.
11 Mar 2025
)
Bob Iger: Disney's Visionary CEO
Bob Iger is a legend in the entertainment industry, known for his visionary leadership and as one of the most influential CEOs in Disney's history.
10 Mar 2025
Ticker symbol
MSB
Country
🇦🇺 Australia